ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma

Zhu, Jinrong; Wu, Yongqi; Yu, Yijian; Li, Yan; Shen, Jianfei*; Zhang, Rongxin*广东药学院
Cell Death & Disease2022-8-20DOI: 10.1038/s41419-022-05180-2
9被引11阅读
引用收藏
分享

摘要

Angiogenesis is considered as an important process in tumor growth, metastasis of hepatocellular carcinoma (HCC) and associated with cancer progression, suggesting that an important research and development field of clinical molecular targeted drugs for HCC. However, the molecular mechanisms underlying tumor angiogenesis in HCC remains elusive. In the current study, we demonstrate that upregulation of AMYB proto-oncogene-like 1 (MYBL1) was associated with high endothelial vessel (EV) density and contributed to poor prognosis of HCC patient. Functionally, MYBL1 overexpressing enhanced the capacity of HCC cells to induce tube formation, migration of HUVECs, neovascularization in CAMs, finally, enhanced HCC cells metastasis, while silencing MYBL1 had the converse effect. Furthermore, HCC cells with high MYBL1 expression were more resistance to sorafenib treatment. We observed that CD31 staining was significantly increased in tumors formed by MYBL1-overexpressing cells but decreased in MYBL1-silenced tumors. Mechanistically, MYBL1 binds to the ANGPT2 promoter and transcriptionally upregulate ANGPT2 mRNA expression. Strikingly, treatment with monoclonal antibody against ANGPT2 significantly inhibited the growth of MYBL1-overexpressing tumors and efficiently impaired angiogenesis. Furthermore, the histone post-translational factors: protein arginine methyltransferase 5 (PRMT5), MEP50, and WDR5 were required for MYBL1-mediated ANGPT2 upregulation. Importantly, we confirmed the correlation between MYBL1 and ANGPT2 expression in a large cohort of clinical HCC samples and several published datasets in pancreatic cancer, esophageal carcinoma, stomach adenocarcinoma, and colon cancer. Our results demonstrate that MYBL1 upregulated the ANGPT2 expression, then induced angiogenesis and confer sorafenib resistance to HCC cells, and MYBL1 may represent a novel prognostic biomarker and therapeutic target for patients with HCC.

学科与关键词

关键词
ANGIOPOIETIN-2GROWTHPRMT5
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Cell Death & Disease
发表日期
2022-08-20
卷期
第 13 卷, 第 8 期
页码
727
DOI
10.1038/s41419-022-05180-2
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82103637]; Guangdong Science and Technology Department [2019A1515110740]; Health Commission of Guangdong Province [A2020100]

作者

  • Z

    Zhu, Jinrong (第一作者)

    guangdong pharmaceut univ

  • W

    Wu, Yongqi

    guangdong pharmaceut univ

查看全部 6 位作者收起作者
  • Y

    Yu, Yijian

    wenzhou med univ

  • L

    Li, Yan

    guangdong pharmaceut univ

  • S

    Shen, Jianfei (通讯)

    wenzhou med univ

  • Z

    Zhang, Rongxin (通讯)

    guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417